» Articles » PMID: 16484453

Selective Stimulation of T Cell Subsets with Antibody-cytokine Immune Complexes

Overview
Journal Science
Specialty Science
Date 2006 Feb 18
PMID 16484453
Citations 481
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-2 (IL-2), which is a growth factor for T lymphocytes, can also sometimes be inhibitory. Thus, the proliferation of CD8+ T cells in vivo is increased after the injection of a monoclonal antibody that is specific for IL-2 (IL-2 mAb), perhaps reflecting the removal of IL-2-dependent CD4+ T regulatory cells (T regs). Instead, we show here that IL-2 mAb augments the proliferation of CD8+ cells in mice simply by increasing the biological activity of preexisting IL-2 through the formation of immune complexes. When coupled with recombinant IL-2, some IL-2/IL-2 mAb complexes cause massive (>100-fold) expansion of CD8+ cells in vivo, whereas others selectively stimulate CD4+ T regs. Thus, different cytokine-antibody complexes can be used to selectively boost or inhibit the immune response.

Citing Articles

SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy.

Kong X, Lin Y, Ouyang C, Chen H, Gao X Drug Des Devel Ther. 2025; 19:1251-1270.

PMID: 40026336 PMC: 11869757. DOI: 10.2147/DDDT.S493011.


CD301b dendritic cell-derived IL-2 dictates CD4 T helper cell differentiation.

Tatsumi N, El-Fenej J, Davila-Pagan A, Kumamoto Y Nat Commun. 2025; 16(1):2002.

PMID: 40011469 PMC: 11865452. DOI: 10.1038/s41467-025-55916-9.


Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.

Faller K, Chaytow H, Gillingwater T Nat Rev Neurol. 2025; 21(2):86-102.

PMID: 39743546 DOI: 10.1038/s41582-024-01049-4.


IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines.

Sobral M, Cabizzosu L, Kang S, Ruark K, Najibi A, Najibi A Proc Natl Acad Sci U S A. 2024; 121(48):e2322356121.

PMID: 39556726 PMC: 11621762. DOI: 10.1073/pnas.2322356121.


A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates.

Ma L, Acuff N, Joseph I, Ptacin J, Caffaro C, San Jose K Cancer Res Commun. 2024; 4(10):2799-2814.

PMID: 39320047 PMC: 11503527. DOI: 10.1158/2767-9764.CRC-24-0278.